Extracellular Vesicle Engineering for Myocardial Remodeling

Abstract

Myocardial remodeling is a complex response to cardiac injury, often culminating in heart failure. The emergence of extracellular vesicles (EVs) as mediators of intercellular communication has revolutionized therapeutic strategies for cardiac repair. This article reviews the latest evidence on engineering EVs for myocardial remodeling, highlights their diagnostic and therapeutic potential, and discusses future prospects for clinical translation. Emphasis is placed on mechanistic insight, clinical relevance, and integration of recent guidelines.

Introduction

Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, with myocardial remodeling representing a critical determinant of patient outcomes following myocardial infarction (MI) and chronic cardiac conditions. Traditional therapies are limited in reversing maladaptive remodeling. Recent advances in the understanding of extracellular vesicles nano-sized, membrane-bound particles released from various cell types have sparked interest in their potential for cardiac regeneration. Engineered EVs offer novel avenues for targeted delivery of bioactive molecules, modulation of immune responses, and promotion of cardiomyocyte survival, positioning them as promising tools for myocardial repair.

Epidemiology / Disease Burden

Myocardial remodeling is a common sequela of acute and chronic ischemic heart diseases. Globally, over 17 million people succumb to cardiovascular diseases each year, with a significant proportion experiencing adverse remodeling that leads to heart failure. Hospitalization rates for heart failure continue to rise, imposing substantial healthcare and socioeconomic burdens. Despite optimal guideline-directed medical therapy, a considerable percentage of patients progress to end-stage heart disease, underscoring the necessity for innovative therapeutic interventions.

Pathophysiology

Myocardial remodeling involves complex structural, cellular, and molecular changes in the heart post-injury. Key processes include cardiomyocyte apoptosis, necrosis, fibroblast activation, extracellular matrix deposition, inflammation, and neurohormonal activation. EVs, including exosomes and microvesicles, play pivotal roles in mediating communication between cardiomyocytes, endothelial cells, fibroblasts, and immune cells. These vesicles carry proteins, lipids, RNAs, and microRNAs that can modulate recipient cell function, influence inflammatory cascades, and regulate fibrotic pathways making them attractive targets for engineering interventions.

Risk Factors

Major risk factors for myocardial remodeling encompass hypertension, diabetes mellitus, dyslipidemia, smoking, genetic predispositions, and recurrent ischemic events. The presence of comorbidities such as chronic kidney disease and persistent inflammatory states further exacerbates adverse remodeling. Understanding patient-specific risk profiles is essential for tailoring EV-based therapies and predicting therapeutic response.

Clinical Features

Patients with myocardial remodeling typically present with symptoms of heart failure, including exertional dyspnea, fatigue, peripheral edema, and reduced exercise tolerance. On clinical examination, findings may include displaced apical impulse, gallop rhythms, and signs of volume overload. Subclinical remodeling can be detected via imaging modalities such as echocardiography and cardiac MRI, which reveal changes in ventricular geometry, wall thickness, and ejection fraction.

Diagnosis

Definitive diagnosis of myocardial remodeling incorporates clinical assessment, biomarker measurement, and advanced imaging. Echocardiography remains the cornerstone for evaluating structural alterations, chamber volumes, and systolic/diastolic function. Cardiac MRI offers superior tissue characterization, enabling detection of fibrosis and myocardial viability. Circulating biomarkers, including natriuretic peptides, troponins, and novel EV-associated microRNAs, aid in risk stratification and monitoring of therapeutic response. Recent studies suggest that engineered EVs themselves could serve as diagnostic tools, given their ability to reflect the molecular state of the myocardium.

Treatment & Management

Current management strategies focus on neurohormonal blockade (using ACE inhibitors, ARBs, beta-blockers, aldosterone antagonists, and SGLT2 inhibitors), device therapy (ICDs, CRT), and lifestyle interventions. Despite these measures, residual risk persists. EV-based therapies aim to directly counteract maladaptive remodeling by delivering reparative signals to the myocardium. Preclinical models have demonstrated that engineered EVs loaded with cardioprotective microRNAs, growth factors, or anti-inflammatory agents can attenuate fibrosis, promote angiogenesis, and improve contractile function. Optimization of EV source, dosage, and delivery route remains an area of active research.

Recent Advances / Emerging Therapies

Recent breakthroughs in EV engineering include surface modification for targeted delivery, encapsulation of therapeutic cargos, and genetic editing to enhance reparative capacity. Mesenchymal stromal cell-derived EVs, for example, have shown efficacy in reducing infarct size and improving cardiac function in animal models. Synthetic EV mimetics and biomaterial-based scaffolds further expand the versatility of this platform. Clinical trials, such as the ongoing exosome-based therapy studies for ischemic heart disease, are poised to clarify safety and efficacy in humans. Biomarker-guided patient selection and personalized EV engineering are emerging concepts that promise to optimize therapeutic outcomes.

Guideline Recommendations

While international cardiovascular societies recognize the importance of myocardial remodeling, explicit recommendations for EV-based therapies await further validation from phase II/III trials. Current guidelines endorse participation in clinical trials and highlight the need for standardized protocols in EV isolation, characterization, and administration. Multidisciplinary collaboration and rigorous regulatory oversight are essential for translating promising preclinical findings into clinical practice.

Conclusion

Extracellular vesicle engineering represents a paradigm shift in the management of myocardial remodeling. By harnessing the innate capacity of EVs to modulate cardiac repair processes, engineered vesicles offer hope for transforming outcomes in patients with refractory heart disease. Ongoing research, multidisciplinary collaboration, and adherence to evolving guidelines will be pivotal in realizing the full therapeutic potential of this innovative approach. As the field advances, EV-based strategies are likely to become integral components of personalized cardiac care.